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Abstract
Insulin-like growth factor-I (IGF-I) and testosterone have been implicated in prostate cancer
aetiology. Using data from a large prospective full-cohort with standardised assays and
repeat blood measurements, and genetic data from an international consortium, we investi-
gated the associations of circulating IGF-I, sex hormone-binding globulin (SHBG), and total
and calculated free testosterone concentrations with prostate cancer incidence and mortality.
For prospective analyses, risk was estimated using multivariable-adjusted Cox regression in
199 698 male UK Biobank participants. Hazard ratios (HRs) were corrected for regression
dilution bias using repeat hormone measurements from a subsample. Two-sample Mendelian
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randomisation (MR) analysis of IGF-I and risk used genetic instruments identified from UK
Biobank men and genetic outcome data from the PRACTICAL consortium (79 148 cases
and 61 106 controls). We used cis- and all (cis and trans) SNP MR approaches. A total of
5402 men were diagnosed with and 295 died from prostate cancer (mean follow-up
6.9 years). Higher circulating IGF-I was associated with elevated prostate cancer diagnosis
(HR per 5 nmol/L increment = 1.09, 95% CI 1.05-1.12) and mortality (HR per 5 nmol/L incre-
ment = 1.15, 1.02-1.29). MR analyses also supported the role of IGF-I in prostate cancer
diagnosis (cis-MR odds ratio per 5 nmol/L increment = 1.34, 1.07-1.68). In observational ana-
lyses, higher free testosterone was associated with a higher risk of prostate cancer (HR per
50 pmol/L increment = 1.10, 1.05-1.15). Higher SHBG was associated with a lower risk
(HR per 10 nmol/L increment = 0.95, 0.94-0.97), neither was associated with prostate cancer
mortality. Total testosterone was not associated with prostate cancer. These findings impli-
cate IGF-I and free testosterone in prostate cancer development and/or progression.
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1 | INTRODUCTION
Prostate cancer is the second most common cancer in men worldwide
and a leading cause of cancer death.1 Few potentially modifiable risk
factors have been identified, but circulating hormone concentrations
are thought to play a role in prostate cancer aetiology.2,3
Insulin-like growth factor-I (IGF-I) is involved in cell proliferation,
differentiation and apoptosis, and prospective studies have shown a
positive association of circulating IGF-I concentration with prostate
cancer risk.4 Less is known about its potential role in prostate cancer
progression or mortality.5
Androgens are integral to the maintenance of normal prostate
function.6 In the circulation, testosterone is bound to sex hormone-
binding globulin (SHBG) and albumin. Approximately 2% of total tes-
tosterone circulates unbound or “free” and is postulated to be biologi-
cally active.7 Observational pooled analysis of individual participant
data from prospective studies indicated that men with very low free
testosterone may have a lower risk of prostate cancer,8 and a recent
Mendelian randomisation (MR) study supports a positive association
between free testosterone concentration and prostate cancer diagno-
sis.9 However, it is unclear whether circulating free testosterone con-
centration is associated with prostate cancer mortality.8,10
Epidemiological studies have also reported an inverse association
between prostate cancer risk and circulating SHBG,8 although results
from MR analyses are inconclusive.9
Previous risk estimates for prostate cancer in relation to hormone
concentration have generally been based on data from nested case-
control studies with a single blood draw at baseline. The UK Biobank
study has standardised measurements of hormones from baseline
blood samples collected in the whole cohort (500 000 participants) as
well as repeat measurements of the hormones in a subset (20 000).
In this article, we aimed to examine the associations of serum
concentrations of IGF-I, SHBG, total and free testosterone with pros-
tate cancer incidence and mortality, using observational data from UK
Biobank. For IGF-I, we investigated potential causal associations of
IGF-I with prostate cancer using MR analyses, with genetic data from
UK Biobank and the PRACTICAL consortium (based on 79 000 pros-
tate cancer cases and 61 000 controls). MR analyses of SHBG, total
and free testosterone and prostate cancer risk using these datasets
have recently been published.9 MR uses germline genetic variants as
proxies of putative risk factors and estimates their associations with
disease. As germline genetic variants are fixed and randomly allocated
at conception, this technique minimises the possibility of confounding
and reverse causality, and is therefore considered a useful approach
towards causal inference.11 By using these two complementary
approaches, we were able to robustly investigate associations and
assess causation.
What's new?
Testosterone, insulin-like growth factor-I (IGF-I), and sex
hormone-binding globulin (SHBG) all have been associated
with prostate-cancer risk. In this large, prospective study, the
authors analyzed how these circulating hormones might
impact mortality as well as risk. They found that men with
higher IGF-I had a higher risk of both prostate-cancer diag-
nosis and mortality. Men with higher free testosterone had
an increased risk of prostate cancer, while men with higher
SHBG had a decreased risk. These results support the roles
of IGF-I and testosterone in prostate cancer development.
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2 | PATIENTS AND METHODS
2.1 | UK Biobank observational analysis
2.1.1 | Study design
UK Biobank is a prospective cohort with open access for public health
research. Details of the study protocol and data collection are avail-
able online (http://www.ukbiobank.ac.uk/wp-content/uploads/2011/
11/UK-Biobank-Protocol.pdf) and elsewhere.12,13
In brief, all participants were registered with the UK National
Health Service (NHS) and lived within 40 km of one of the UK
Biobank assessment centres. Approximately 9.2 million people
were initially invited to participate. Overall, 503 317 men and
women aged 40 to 69 years consented to join the cohort and
attended one of 22 assessment centres throughout England,
Wales and Scotland between 2006 and 2010, a participation rate
of 5.5%.13
2.1.2 | Baseline assessment
At the baseline assessment visit, participants provided information on
a range of sociodemographic, physical, lifestyle and health-related fac-
tors via a self-completed touchscreen questionnaire and a computer-
assisted personal interview.13 Weight and height were measured at
the assessment centre.13
2.1.3 | Blood sampling and biomarker assays
At recruitment, blood sampling was successfully performed in
99.7% of the cohort. Blood was collected in a serum separator tube
and shipped to the central processing laboratory in temperature-
controlled boxes at 4C,14 then aliquoted and stored in a central
working archive at −80C.15 Serum concentrations of circulating
IGF-I, SHBG, testosterone and albumin were measured in all partic-
ipants. IGF-I (DiaSorin Liaison XL), SHBG and testosterone
(Beckman Coulter AU5800) were determined by chemiluminescent
immunoassays. Albumin was measured by a colorimetric assay
(Beckman Coulter AU5800). Average within-laboratory (total) coef-
ficients of variation for low, medium and high internal quality con-
trol level samples for each biomarker ranged from 2.1% to 8.3%.
Full details of the assay methods and quality assurance protocols
are available online (https://biobank.ndph.ox.ac.uk/showcase/
docs/serum_biochemistry.pdf).
2.1.4 | Free testosterone estimation
Free testosterone concentrations were estimated using a formula
based on the law of mass action from measured total testosterone,
SHBG and albumin concentrations.16,17
2.1.5 | Repeat assessment
Participants who lived within a 35 km radius were invited to attend a
repeat assessment clinic at the UK Biobank Co-ordinating Centre in
Stockport between August 2012 and June 2013. Repeat assessments
were completed in 20 000 participants (9000 men) with a response
rate of 21%.18
2.1.6 | Participant follow-up
Cancer registration data were provided via record linkage to the NHS Cen-
tral Register and obtained via NHS Digital, until the censoring date
(31 March 2016 in England and Wales and 31 October 2015 in Scotland).
Death data for England and Wales were provided by NHS Digital and for
Scotland by the Information and Statistics Division (censoring dates
31 January 2018 in England and Wales, and 30 November 2016 in Scot-
land). In the analysis of incident prostate cancer, the endpoint was defined
as the first diagnosis of prostate cancer, or prostate cancer mortality (pri-
mary or otherwise) (International Classification of Diseases Tenth revision
code [ICD-10] C6119), whichever was recorded first. In the analysis of pros-
tate cancer mortality, the endpoint was prostate cancer as the primary cause
of death. Person-years were calculated from the date of recruitment to the
date of the first cancer registration (excluding non-melanoma skin cancer
[ICD-10 C44]), death or censoring date, whichever occurred first.
2.1.7 | Exclusion criteria
Our analytical dataset included 199 698 men; we excluded 9871 men
with prevalent cancer (except C44: non-melanoma skin cancer),
13 509 men who did not have blood data available or who had bio-
marker measurements that did not pass quality control procedures,20
1685 participants for whom it was not possible to determine genetic
sex or who were identified as being genetically female, 2326 men
who reported taking hormone medication at baseline and 758 men
who had no body mass index (BMI) data.
2.1.8 | Statistical analysis
Hazard ratios (HRs) and 95% confidence intervals (CIs) of prostate cancer
diagnosis and mortality were estimated using Cox proportional hazards
models, with age as the underlying time variable. Analyses were stratified by
geographic area (10 UK regions) and age at recruitment (<45, 45-49, 50-54,
55-59, 60-64, ≥65 years), and adjusted for Townsend deprivation score
(fifths, unknown [0.1%]), racial/ethnic group (white, mixed background,
Asian, black, other and unknown [0.5%]), height (<170, ≥170-<175,
≥175-<180, ≥180 cm and unknown [0.1%]), lives with a wife or partner (no,
yes), body mass index (BMI) (<25, ≥25-<30, ≥30-<35, ≥35 kg/m2), cigarette
smoking (never, former, current light smoker (1-<15 cigarettes per day), cur-
rent heavy smoker (≥15 cigarettes per day), current (number of cigarettes
per day unknown) and smoking status unknown [0.6%]), alcohol
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consumption (non-drinkers, <1-<10, ≥10-<20, ≥20 g ethanol/day, unknown
[0.5%]), and self-reported diabetes (no, yes and unknown [0.5%]). Adjust-
ment covariates were defined a priori based on previous analyses of UK
Biobank data and categories were used to allow for nonlinear
associations.21
Blood biomarker measurements were also available for up to
7776 men who attended a repeat assessment clinic a median of
4.4 years after first blood collection.18 Measurement error and within
person variability using single measures at baseline leads to underesti-
mation of risk (ie, regression dilution bias),22 to provide more precise and
generalisable risk estimates, HRs for trend were estimated per absolute
increase in usual hormone concentrations, with correction for regression
dilution bias using the McMahon-Peto method.22,23
In the categorical analyses, biomarker measurements were cat-
egorised into fifths based on the distribution in the whole cohort and
HRs were calculated relative to the lowest fifth of each blood parame-
ter. The variance of the log risk in each group was calculated (from
the variances and covariances of the log risk) and used to obtain
group-specific 95% CIs, which enable comparisons across different
exposure categories.24
The proportional hazards assumption was examined using time-
varying covariates and Schoenfeld residuals and revealed no evidence
of deviation.
2.1.9 | Subgroup analyses
Subgroup analyses for incident prostate cancer were examined by the
following categories: age at diagnosis (≤65, >65 years), time from blood
collection to diagnosis (≤4, >4 years), age at blood collection (<60,
≥60 years), BMI (<30, ≥30 kg/m2), smoking status (never or former, cur-
rent), alcohol consumption (<10, ≥10 g ethanol/day), education status
(no university degree, university degree), currently married/cohabiting
(no, yes), Townsend index (<median, ≥median), ethnicity (white, non-
white), height (≤175, >175 cm), diabetes (no, yes), family history of pros-
tate cancer (no, yes), poor self-rated health (no, yes) and median
observed hormone concentrations (<median, ≥median). Subgroup cate-
gories were chosen a priori on the basis of data distributions and previ-
ous analyses by this research group.4,8 Heterogeneity in the associations
for case-specific variables (ie, age at diagnosis and time from blood col-
lection to diagnosis) was examined using stratified Cox models based on
competing risks and comparing the risk coefficients and standard errors
in the two subgroups, and testing with a χ2 for heterogeneity. For non-
case-specific factors, heterogeneity was assessed using a χ2 interaction
term. Heterogeneity in the associations with prostate cancer mortality
was not tested due to the limited statistical power.
2.1.10 | Further analyses
We examined the association of IGF-I with incident prostate cancer
after additional adjustment for concentrations of free testosterone
and SHBG, and the associations of total and free testosterone and
SHBG after further adjustment for IGF-I (with adjustment for bio-
markers categorised into fifths and unknown). As a further examina-
tion of trend, the categorical variable representing the fifths of the
hormones was replaced with a continuous variable that was scored as
0, 0.25, 0.5, 0.75 and 1, such that a unit increase in this variable can
be taken to represent an 80 percentile increase in concentrations to
enable comparison across hormones and with previous pooled ana-
lyses.4,8 Analyses with prostate cancer diagnosis were repeated after
hormone concentrations were divided into tenths.
2.2 | Mendelian randomisation analyses
2.2.1 | Genetic associations with circulating IGF-I
Single nucleotide polymorphisms (SNPs) associated with circulating IGF-I
(P < 5 × 10−8 significance threshold) were identified from a publicly avail-
able genome wide association study (GWAS) from 167 174 male UK
Biobank participants of European ancestry.25 SNPs were pruned by a
linkage disequilibrium (LD) threshold of r2 < 0.001. UK Biobank
genotyping details are reported elsewhere.26
GWAS results were partitioned into one primary cis-SNP instru-
ment within the IGF-I gene region on chromosome 12 (rs5742653),
and 121 additional trans-SNPs (SNPs associated with circulating IGF-I
concentrations that are not located in this gene region). These cis and
trans-SNPs together explained 6.3% of the variance in circulating con-
centrations of IGF-I.27 SNP rs numbers, nearest gene and effect esti-
mates are displayed in Supplementary Table S1.
2.2.2 | Genetic instruments for prostate cancer
We used summary statistics for SNP associations with prostate cancer risk
that were generated from 79 148 prostate cancer cases and 61 106 controls
of European ancestry from the PRACTICAL, CRUK, CAPS, BPC3 and PEGA-
SUS consortia.28,29 In brief, 44 825 prostate cancer cases and 27 904 controls
were genotyped using OncoArray (http://epi.grants.cancer.gov/oncoarray/),
and data were also available from several previous prostate cancer GWAS:
UK stage 1 and stage 2; CaPS 1 and CaPS 2; BPC3; NCI PEGASUS; and
iCOGS. Genotype information was imputed for all samples using the October
2014 release of the 1000 Genomes Project data as the reference panel. Odds
ratios (ORs) and SEs were estimated using logistic regression and then meta-
analysed using an inverse variance fixed-effect approach.
Where genetic instruments in the two datasets were not identi-
cal, we used HaploReg30 to identify SNPs in linkage disequilibrium
(r2 > 0.8) to use as proxies.
2.2.3 | Statistical analysis
We used a two-sample MR approach to estimate IGF-I associations
with overall prostate cancer risk, using UK Biobank as our genetic
instruments for IGF-I and PRACTICAL for genetic outcome analyses.
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The MR estimation for IGF-I and prostate cancer was conducted
by the Wald ratio using the cis-SNP (rs5742653). We also conducted
analyses incorporating all 122 IGF-I associated SNPs using the inverse-
variance weighted method, as well as weighted median and mode-based
methods to reduce the influence of pleiotropy.31 The MR pleiotropy
residual sum and outlier (MR-PRESSO) test was used to investigate the
role of outliers.32 To further assess the potential presence of horizontal
pleiotropy, we used Cochran's Q for heterogeneity31 and the intercept
from the MR-Egger method. Additionally, we used leave-one-out ana-
lyses to test the sensitivity of our results to single SNP effects. Phe-
noScanner was used to assess pleiotropy of the genetic instruments.33,34
All analyses were performed using Stata version 14.1 (Stata Cor-
poration, College Station, TX) and R version 3.2.3. All tests of signifi-
cance were two-sided, and P values <.05 were considered statistically
significant. MR analyses were performed using the TwoSampleMR R
package.35
3 | RESULTS
3.1 | UK Biobank observational analyses
After a mean follow-up of 6.9 years (SD = 1.3 years), 5402 (2.7%)
men were diagnosed with prostate cancer and 295 died from the dis-
ease. Table 1 summarises the baseline characteristics of study partici-
pants. Mean age at recruitment was 56.5 years (SD = 8.2), and mean
BMI was 27.8 kg/m2. 29% reported having had a prostate-specific
antigen (PSA) test prior to baseline and 14% had a family history of
TABLE 1 Baseline characteristics and blood data for all men and for men who developed prostate cancer in UK Biobank
All men (N = 199 698)
Men who developed prostate cancer
(N = 5402)
Sociodemographic
Age at recruitment (years), mean (SD) 56.5 (8.19) 62.1 (5.26)
Most deprived quintile, % (N) 19.7 (39280) 15.8 (854)
Black ethnicity, % (N) 1.45 (2882) 2.18 (117)
Not in paid/self-employment, % (N) 38.3 (76448) 56.7 (3062)
Living with partner, % (N) 92.9 (152616) 95.5 (4281)
Anthropometric, mean (SD)
Height (cm) 175.7 (6.84) 175.1 (6.68)
BMI (kg/m2) 27.8 (4.23) 27.5 (3.79)
Lifestyle, % (N)
Current cigarette smokers 12.5 (24855) 9.35 (502)
Drinking alcohol ≥20 g per day 43.7 (86905) 42.7 (2298)
Low physical activity (0–10 METs per
week)
28.1 (54408) 26.6 (1393)
Health history, % (N)
Hypertension 52.2 (104099) 58.6 (3163)
Diabetes 6.82 (13545) 5.91 (318)
Poor self-rated health 4.81 (9547) 3.14 (169)
Prostate-specific factors, % (N)
Ever had a PSA test 28.7 (54139) 46.5 (2396)
Family history of prostate cancer 13.6 (14925) 25.0 (703)
Baseline blood measures, mean (SD)
IGF-I (nmol/L) 21.9 (5.52) 21.6 (5.23)
SHBG (nmol/L) 39.5 (16.6) 41.9 (16.0)
Total testosterone (nmol/L) 12.0 (3.65) 12.0 (3.53)
Free testosterone (pmol/L) 209 (59.5) 200 (54.5)
Albumin (g/L) 45.6 (2.61) 45.2 (2.53)
Abbreviations: BMI, body mass index; IGF-I, insulin-like growth factor-I; METs, metabolic equivalent of tasks; PSA, prostate-specific antigen; SHBG, sex
hormone-binding globulin.
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prostate cancer. Means and SDs for baseline biomarker measure-
ments are displayed in Table 1. Regression dilution ratios ranged
between 0.57 (free testosterone) and 0.80 (IGF-I) (Supplementary
Table S2).
3.1.1 | Associations between hormone
concentrations and prostate cancer risk
Serum IGF-I concentration was positively associated with prostate
cancer incidence (HR per 5 nmol/L increment = 1.09, 95% CI 1.05-
1.12; Ptrend < .0001, Figure 1) and prostate cancer mortality (HR per
5 nmol/L increment =1.15, 95% CI 1.02-1.29; Ptrend = .03, Figure 2).
Serum SHBG concentration was inversely associated with pros-
tate cancer incidence (HR per 10 nmol/L increment = 0.95, 95% CI
0.94-0.97; Ptrend < .0001, Figure 1), but was not associated with pros-
tate cancer mortality (Figure 2). Free testosterone was positively asso-
ciated with prostate cancer incidence (HR per 50 pmol/L
increment = 1.10, 95% CI 1.05-1.15; Ptrend < .0001, Figure 1) but not
with mortality. Total testosterone was not associated with prostate
cancer incidence or mortality.
Risk estimates with and without adjustment for regression dilu-
tion bias are shown in Supplementary Table S2.
3.1.2 | Subgroup analyses
There was no evidence of heterogeneity in the associations of IGF-I
with incident prostate cancer by any of the selected characteristics
(Figure 3). There was some evidence that the inverse association
between SHBG and prostate cancer incidence varied by IGF-I concen-
tration (Phet = .02); only men with lower concentrations of IGF-I (< the
study median) had a reduced risk of prostate cancer (HR per 10 nmol/
L increment in SHBG = 0.94, 95% CI 0.92-0.97, Figure 4).
There was no evidence of heterogeneity in the associations of
total or free testosterone with prostate cancer incidence by any char-
acteristics except for diabetes status. For free testosterone, there was
evidence that the magnitude of the association with incident prostate
cancer was greater in men who were diabetic at baseline (HR per
50 pmol/L increment = 1.19, 95% CI 1.10-1.29) than in those who
were not (HR = 1.05, 95% CI 1.02-1.07; Phet = .004, Figure 5). Total
testosterone was also associated with prostate cancer in men with
Type II diabetes, but not in men without diabetes (Supplementary
Figure S2).
3.1.3 | Further analyses
Associations with incident prostate cancer remained broadly simi-
lar when the associations were examined across tenths of the dis-
tributions (Supplementary Figure S1), and per 80 percentile
increase (Supplementary Table S3). Minimally adjusted results are
displayed in Supplementary Table S4. Mutual adjustment for
hormones did not materially affect the risk estimates (Supplemen-
tary Table S4).
3.2 | Mendelian randomisation
MR analysis using the cis-SNP found that IGF-I was significantly asso-
ciated with a 34% increased prostate cancer risk per 5 nmol/L incre-
ment (95% CI 1.07-1.68; P = .01) (Table 2; Supplementary Figure S3).
MR analysis including all the SNPs (both the cis and trans-SNPs)
found suggestive evidence between IGF-I and prostate cancer diagno-
sis in the same direction as the cis-SNP results (inverse-variance
weighted OR for a genetically predicted 5 nmol/L increment in IGF-
I = 1.06, 95% CI 1.00-1.13; P = .06, Table 2). Although the Egger inter-
cept did not indicate the presence of directional pleiotropy, significant
heterogeneity (Cochran's Q P < .0001) may have influenced SE esti-
mation for the inverse-variance weighted estimate (Table 2). Results
were consistent following the removal of outliers identified using the
MR-PRESSO outlier test (Table 2), and leave-one-out analyses, includ-
ing removal of the cis-SNP (data not shown).
There is no direct functional evidence for the cis-SNP. However,
this SNP is in modest linkage disequilibrium with the SNPs
rs17727841, rs10860864, rs5742671, rs1996656 and rs11111250,
which are expression quantitative trait loci (eQTLs) associated with
IGF1 and WASHC3 expression.36 PheWAS using published data
showed the cis-SNP was associated with measures of lung function
and adiposity (Supplementary Table S5). There was a large amount of
pleiotropy in the trans genetic instruments, for example, for the top
100 trans-SNPs most strongly associated with IGF-I, there were
>2500 published genome-wide significant associations (using the Phe-
noScanner resource).
4 | DISCUSSION
Our observational and MR analyses provide strong evidence that men
with higher circulating IGF-I have an elevated risk of prostate cancer;
furthermore, our observational analyses suggest a higher risk of pros-
tate cancer mortality in these men, suggesting that IGF-I is associated
with risk for more severe forms of prostate cancer and/or may
increase the risk of prostate cancer progression. Higher serum-free
testosterone was associated with a higher risk of prostate cancer
diagnosis, which is supported by a recent MR analysis.9 We also found
that men with a higher SHBG had a lower risk. Total testosterone con-
centration was not associated with prostate cancer incidence or
mortality.
The findings of a likely causal effect of IGF-I in prostate cancer
development may be due to its role in activating signalling pathways,
which regulate cell proliferation and apoptosis.2 The positive relation-
ship between IGF-I and incident prostate cancer observed is consis-
tent with previous epidemiological evidence,4 as well as associations
observed with other cancers including breast and colorectal.37-39 Fur-
ther genetic epidemiology including fine mapping may help elucidate
WATTS ET AL. 2279
P
trend





 = .41) Ptrend < .0001)
F IGURE 1 Hazard ratios of incident prostate cancer by fifths of usual serum hormone concentrations in UK Biobank. HRs are stratified by
region (10 UK cancer registry regions) and age at recruitment (<45, 45-49, 50-54, 55-59, 60-64 and ≥65 years) and adjusted for age (underlying
time variable), Townsend deprivation score (fifths, unknown), racial/ethnic group (white, mixed background, Asian, black, other unknown), height
(<170, ≥170-<175, ≥175-<180, ≥180 cm, unknown), lives with a wife or partner (no, yes), BMI (<25, ≥25-<30, ≥30-<35, ≥35 kg/m2), cigarette
smoking (never, former, light smoker, heavy smoker, current unknown and smoking status unknown), alcohol consumption (non-drinkers, <1-<10,
≥10-<20, ≥20 g ethanol/day, unknown) and diabetes (no, yes and unknown). HRs for trend are adjusted for regression dilution bias. The boxes
represent the HRs; the vertical lines represent the 95% CIs, with the size inversely proportional to the variance of the logarithm of the HR. The
numbers above the vertical lines are point estimates for HRs, and the numbers below are the number of prostate cancer diagnoses. BMI, body
mass index; CI, confidence intervals; HR, hazard ratio; IGF-I, insulin-like growth factor-I; SHBG, sex hormone-binding globulin
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F IGURE 2 Hazard ratios of prostate cancer mortality by fifths of usual serum hormone concentrations in the UK Biobank. HRs are stratified
by region (10 UK cancer registry regions) and age at recruitment (<45, 45-49, 50-54, 55-59, 60-64, and ≥65 years) and adjusted for age
(underlying time variable), Townsend deprivation score (fifths, unknown), racial/ethnic group (white, mixed background, Asian, black, other,
unknown), height (<170, ≥170-<175, ≥175-<180, ≥180 cm, unknown), lives with a wife or partner (no, yes), BMI (<25, ≥25-<30, ≥30-<35,
≥35 kg/m2), cigarette smoking (never, former, light smoker, heavy smoker, current unknown and smoking status unknown), alcohol consumption
(non-drinkers, <1-<10, ≥10-<20, ≥20 g ethanol/day, unknown) and diabetes (no, yes and unknown). HRs for trend are adjusted for regression
dilution bias. The boxes represent the HRs; the vertical lines represent the 95% CIs, with the size inversely proportional to the variance of the
logarithm of the HR. The numbers above the vertical lines are point estimates for HRs, and the numbers below are the number of prostate cancer
deaths. BMI, body mass index; CI, confidence intervals; HR, hazard ratio; IGF-I, insulin-like growth factor-I; SHBG, sex hormone-binding globulin



















F IGURE 3 Hazard ratios of incident prostate cancer per 5 nmol/L increase in serum IGF-I concentration by subgroup in the UK Biobank. Cox
models based on competing risks and compared the risk coefficients and SEs in the two subgroups and tested using a χ2 test of heterogeneity.
For non-case specific factors, heterogeneity was assessed using a χ2 interaction term. HRs are stratified by region (10 UK cancer registry regions)
and age at recruitment (<45, 45-49, 50-54, 55-59, 60-64, and ≥65 years) and adjusted for age (underlying time variable), Townsend deprivation
score (fifths, unknown), racial/ethnic group (white, mixed background, Asian, black, other, unknown), height (<170, ≥170-<175, ≥175-<180,
≥180 cm, unknown), lives with a wife or partner (no, yes), BMI (<25, ≥25-<30, ≥30-<35, ≥35 kg/m2), cigarette smoking (never, former, light
smoker, heavy smoker, current unknown and smoking status unknown), alcohol consumption (non-drinkers, <1-<10, ≥10-<20, ≥20 g ethanol/day,
unknown) and diabetes (no, yes and unknown). The boxes represent the HRs; the horizontal lines represent the 95% CIs, with the size inversely
proportional to the variance of the logarithm of the HR. (1) Not adjusted for regression dilution bias. (2) Adjusted for regression dilution bias. BMI,
body mass index; CI, confidence intervals; HR, hazard ratio; IGF-I, insulin-like growth factor-I; PCa, prostate cancer

















F IGURE 4 Hazard ratio of incident prostate cancer per 10 nmol/L increase in serum SHBG concentration by subgroup in the UK Biobank. Cox
models based on competing risks and compared the risk coefficients and SEs in the two subgroups and tested using a χ2 test of heterogeneity. For non-
case-specific factors, heterogeneity was assessed using a χ2 interaction term. HRs are stratified by region (10 UK cancer registry regions) and age at
recruitment (<45, 45-49, 50-54, 55-59, 60-64 and ≥65 years) and adjusted for age (underlying time variable), and adjusted for Townsend deprivation
score (fifths, unknown), racial/ethnic group (white, mixed background, Asian, black, other, unknown), height (<170, ≥170-<175, ≥175-<180, ≥180 cm,
unknown), lives with a wife or partner (no, yes), BMI (<25, ≥25-<30, ≥30-<35, ≥35 kg/m2), cigarette smoking (never, former, light smoker, heavy
smoker, current unknown and smoking status unknown), alcohol consumption (non-drinkers, <1-<10, ≥10-<20, ≥20 g ethanol/day, unknown) and
diabetes (no, yes and unknown). The boxes represent the HRs; the horizontal lines represent the 95% CIs, with the size inversely proportional to the
variance of the logarithm of the HR. (1) Not adjusted for regression dilution bias. (2) Adjusted for regression dilution bias. BMI, body mass index; CI,
confidence intervals; HR, hazard ratio; PCa, prostate cancer; SHBG, sex hormone-binding globulin
















F IGURE 5 Hazard ratio of incident prostate cancer per 50 pmol/L increase in serum free testosterone concentration by subgroup in the UK Biobank.
Cox models based on competing risks and compared the risk coefficients and SEs in the two subgroups and tested using a χ2 test of heterogeneity. For non-
case-specific factors, heterogeneity was assessed using a χ2 interaction term. HRs are stratified by region (10 UK cancer registry regions) and age at
recruitment (<45, 45-49, 50-54, 55-59, 60-64, and ≥65 years) and adjusted for age (underlying time variable), and adjusted for Townsend deprivation score
(fifths, unknown), racial/ethnic group (white, mixed background, Asian, black, other, unknown), height (<170, ≥170-<175, ≥175-<180, ≥180 cm, unknown),
lives with a wife or partner (no, yes), BMI (<25, ≥25-<30, ≥30-<35, ≥35 kg/m2), cigarette smoking (never, former, light smoker, heavy smoker, current
unknown and smoking status unknown), alcohol consumption (non-drinkers, <1-<10, ≥10-<20, ≥20 g ethanol/day, unknown) and diabetes (no, yes and
unknown). The boxes represent the HRs; the horizontal lines represent the 95% CIs, with the size inversely proportional to the variance of the logarithm of
the HR. (1) Not adjusted for regression dilution bias. (2) Adjusted for regression dilution bias. BMI, body mass index; CI, confidence intervals; HR, hazard ratio;
PCa, prostate cancer
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exactly by which mechanism variation at the IGF1 locus associates
with risk of prostate and some other cancers.
Our finding of a positive association between calculated free tes-
tosterone concentration and prostate cancer diagnosis is consistent
with the importance of androgens for prostate cancer development,3
previous evidence from pooled nested case–control studies,8
randomised controlled trials that aim to reduce intraprostatic andro-
gen signalling40,41 and MR analyses.9 However, the shape of the asso-
ciation between circulating free testosterone and prostate cancer risk
is not completely clear; here we see an approximately linear associa-
tion, whereas our previous pooled analysis suggested that very low
free testosterone concentrations were associated with a lower pros-
tate cancer risk, but that risk did not change with further increments
in free testosterone concentration.8
There is some evidence to suggest that men with low free testos-
terone may have an increased risk of high-grade prostate tumours,
but the data are inconclusive.8,40-42 In this analysis, prostate cancer
mortality was used as a proxy of tumour aggressiveness; we did not
observe an association between circulating total or free testosterone
concentrations and prostate cancer mortality, although statistical
power to examine this association was limited (<300 prostate cancer
deaths).
Men with higher SHBG concentrations had a lower risk of pros-
tate cancer, which is consistent with previous prospective studies.8
MR analyses have also shown some evidence of an inverse relation-
ship, but results were not statistically significant.9 In the current study,
we cannot determine whether the mechanism underlying this associa-
tion relates to SHBG itself or to the action of SHBG as a carrier pro-
tein, which modulates androgen access to tissues.
This analysis has several strengths. It is the largest prospective
full-cohort analysis to examine hormones in relation to prostate can-
cer incidence and mortality. UK Biobank is a well-characterised study
population, and therefore we were able to adjust our risk results for a
wide range of possible confounders and to investigate associations in
a number of subgroups. Our results were consistent across these sub-
groups; in only three subgroup analyses, there was weak evidence of
heterogeneity in the associations with prostate cancer risk. We
observed heterogeneity in the associations of total and free testoster-
one by diabetes status. This heterogeneity may be related to hormone
differences in diabetic men, who have a lower risk of prostate cancer
diagnosis.21 However, men with diabetes also have lower PSA con-
centrations, which reduces the probability of prostate cancer detec-
tion43,44 and may lead to differential bias of our risk estimates; we are
also unable to rule-out chance due to multiple testing and the small
numbers of men with diabetes and subsequent prostate cancer
(n = 283-311). Hormones were measured using a standardised
method; therefore, we were able to estimate risk associations of the
absolute scale and use repeat measurements to improve the precision
of risk estimates.22 Furthermore, by incorporating both observational
and MR methods, we were able to use different lines of evidence with
orthogonal biases to investigate the potential causality of the associa-
tions of IGF-I with prostate cancer risk.45 Our MR analysis of IGF-I
using a cis-SNP is an example of the strongest case for an MR analysis,
due to the strong plausibility of a biological link and a reduced likeli-
hood of horizontal pleiotropy46,47; therefore the association for this
cis-SNP indicates that IGF-I may be driving the reported associations
with prostate cancer risk.
A limitation of the analysis is that prostate tumour stage and
grade information are not currently available in the UK Biobank, and
only incident prostate cancer data are available in the MR analyses.
The UK Biobank participants are predominantly white and healthier
than the sampling population; therefore, selection bias may influence
the results48 and risk estimates may not be generalisable,13 although
this is unlikely to affect the direction of the associations.49 Relatively
weak evidence from MR analyses incorporating all GWAS significant
SNPs for IGF-I may reflect widespread pleiotropy for trans-SNPs
including the IGFBPs and IGF-II signalling, which served as primary
motivation to emphasise the association of the cis-variant. A limitation
of the use of this cis instrument is the lack of direct functional evi-
dence; however, the identification of an individual SNP linked to an
eQTL is difficult because of the high collinearity of SNPs. There was
some evidence that SNPs in modest linkage disequilibrium with the
cis-variant alter the expression levels of IGF1 and WASHC3. Due to
the strong association of rs5742653 with circulating IGF-I concentra-
tions, it's location within the IGF1 gene region, and the lack of any
other biological evidence linking WASHC3 to prostate cancer risk, we
consider that the use of this cis-SNP is valid. The effect estimates
from the MR analyses were calculated on the same scale as for the
observational analyses, and this scaling-up results in some imprecision
with wide confidence intervals in the association with the cis-SNP;
TABLE 2 Mendelian randomisation estimates between genetically predicted circulating IGF-I concentrations and prostate cancer risk
Method
OR per genetically predicted
5 nmol/L increase in IGF-I (95% CI) P value
cis-SNP (N = 1) Wald ratio 1.34 (1.07–1.68) .01
All SNPs (trans- and cis-SNPs, N = 122) Inverse weighted variance 1.06 (1.00–1.13) .06
Weighted median 1.03 (0.96-1.11) .43
Weighted mode 0.99 (0.87-1.11) .82
MR-Egger 1.04 (0.90-1.20) .57
MR-PRESSO 1.06 (1.00-1.12) .04
Abbreviations: CI, confidence interval; IGF-I, insulin-like growth factor-I; OR, odds ratio; SNP, single nucleotide polymorphism.
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the concordance of the directions of the associations is particularly
important.
Testosterone is related to other androgens, which have not been
measured in UK Biobank; therefore, associations may be at least par-
tially be explained by other androgens, although there is little observa-
tional evidence to support this.50 Free testosterone concentrations
were estimated using a commonly employed formula derived from
mass action equations, and the results may not correspond precisely
to free testosterone measured using equilibrium dialysis.51 SHBG cir-
culates as a homodimer, which presents two binding sites for testos-
terone adding further complexity to calculation of free testosterone.7
Furthermore, experimental evidence postulates entry of SHBG-bound
testosterone into cells via megalin, an endocytic receptor expressed in
reproductive tissues.52 Therefore, the predictive value of calculated
free testosterone as an indicator of the bioavailability of testosterone
to the cells within the prostate remains under debate.53 Measurement
of serum-free testosterone using equilibrium dialysis may improve the
accuracy of risk estimates, but this methodology is labour-intensive
and not readily available.
PSA concentrations are partly regulated by the androgen recep-
tor54; lower free testosterone concentrations may therefore reduce
circulating PSA concentrations, reducing the likelihood of prostate
cancer detection (possibly as well as reducing the likelihood of cancer
development). Comorbidities, socioeconomic status and poor health
may affect PSA test attendance, but PSA testing attendance after
baseline was not known.
In conclusion, our results implicate IGF-I and free testosterone in
prostate cancer development and/or progression. This analysis of
200 000 men enabled us to quantify the associations of circulating
hormone concentrations with prostate cancer risk. The complemen-
tary MR for IGF-I supports a causal association. Future research will
examine hormone associations by tumour stage and grade.
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